Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session: Breast cancer, metastatic

LBA20 - Open-label, randomized study of lasofoxifene (LAS) vs fulvestrant (Fulv) for women with locally advanced/metastatic ER+/HER2- breast cancer (mBC), an estrogen receptor 1 (ESR1) mutation, and disease progression on aromatase (AI) and cyclin-dependent kinase 4/6 (CDK4/6i) inhibitors


10 Sep 2022


Mini Oral session: Breast cancer, metastatic


Clinical Research;  Endocrine Therapy;  Targeted Therapy

Tumour Site

Breast Cancer


Matthew Goetz


Annals of Oncology (2022) 33 (suppl_7): S808-S869. 10.1016/annonc/annonc1089


M.P. Goetz1, P. Plourde2, D.G. Stover3, N. Bagegni4, G.A. Vidal5, A. Brufsky6, H.S. Rugo7, D.J. Portman2, E. Gal-Yam8

Author affiliations

  • 1 Department Of Oncology, Mayo Clinic, 55905 - Rochester/US
  • 2 Oncology Clinical Development, Sermonix Pharmaceuticals, 43209 - Columbus/US
  • 3 460 W. 12th Avenue, Biomedical Research Tower, Room 512, OSUCCC - The Ohio State University Comprehensive Cancer Center - James, 43210 - Columbus/US
  • 4 Division Of Medical Oncology, Washington University School of Medicine in St. Louis - Siteman Cancer Center, 63110 - St. Louis/US
  • 5 Medical Oncology Department, West Cancer Center and Research Institute - East Campus, 38138 - Germantown/US
  • 6 Division Of Hematology/oncology, Comprehensive Breast Cancer Center, University of Pittsburgh Medical Center, 15213 - Pittsburgh/US
  • 7 Breast Department, UCSF Helen Diller Family Comprehensive Cancer Center, 94158 - San Francisco/US
  • 8 Oncology Institute, Chaim Sheba Medical Center, 52621 - Ramat Gan/IL


This content is available to ESMO members and event participants.

Abstract LBA20


Acquired ESR1 mutations cause endocrine resistance, driving metastasis and poor prognosis in patients with ER+/HER2- mBC. A phase 2 trial of LAS plus abemaciclib (ELAINE 2) showed efficacy in heavily pretreated patients with ESR1-mutated mBC post-CDK4/6i (ASCO 2022). Here we describe ELAINE 1, a randomized trial of LAS vs Fulv in a post-CDK4/6i second-line setting.


Women with ER+/HER2-/ESR1-mutated mBC and progression on prior (≥12 mos) AI plus CDK4/6i (n=103) were randomized to oral LAS 5 mg (n=52) daily or IM Fulv 500 mg (n=51) days 1, 15, and 29, then every 4 weeks, until disease progression or severe toxicity. Imaging occurred every 2 mos (or if clinically indicated). Primary endpoint was progression-free survival (PFS).


Mean age was 60.8 yr (33-84); 83% were white, 66% had visceral disease, 71% (n=73) had measurable disease. For LAS vs Fulv, median PFS was 6.04 mos (95% CI, 2.82–8.04) vs 4.04 mos (95% CI, 2.93–6.04), P=0.138 (HR, 0.699 [95% CI, 0.445–1.125]); PFS at 12 mos was 30.7% vs 14.1%; clinical benefit rate was 36.5% vs 21.6%, P=0.12. Objective response rate for LAS vs Fulv was 13.2% vs 2.9%, P=0.12, with 1 complete response (60-week duration) and 4 partial responses (PR) in the LAS arm versus 1 PR in the Fulv arm. PFS was numerically and consistently greater with LAS vs Fulv when visceral metastasis and/or Y537S ESR1 mutation subgroups were analyzed. Clearance of ctDNA also favored LAS over Fulv. Most common adverse events were fatigue, nausea, arthralgias, and hot flushes; most were Grade 1/2. No thrombotic events occurred.


ELAINE 1 is the first clinical trial comparing LAS with Fulv in ESR1-mutated mBC patients with progression on CDK4/6i and demonstrating activity of a novel SERM in this setting. All clinical outcomes numerically favored LAS vs Fulv in this signal-seeking study. LAS may be a new treatment option following endocrine/CDK4/6i therapies if efficacy is confirmed in a larger, adequately powered clinical study. A phase 3 combination study of LAS and abemaciclib is planned based on encouraging efficacy/safety in ELAINE 2.

Clinical trial identification


Editorial acknowledgement

Medical writing assistance was provided by Kathleen Ohleth, PhD of Precise Publications, LLC.

Legal entity responsible for the study

Sermonix Pharmaceuticals.


Sermonix Pharmaceuticals.


M.P. Goetz: Financial Interests, Institutional, Advisory Role: Mayo Clinic, Biovica, Biotheranostics, Blueprint Medicines, Eagle Pharmaceuticals, Lily, Novartis, Pfizer, Sanofi Genzyme, Sermonix; Financial Interests, Personal, Invited Speaker: Research to Practice, Clinical Education Alliance, Medscape, Total Health Conferenceing, Curio Science; Financial Interests, Institutional, Research Grant: Mayo Clinic, Pfizer, Sermonix. P. Plourde: Financial Interests, Personal, Full or part-time Employment: Sermonix; Financial Interests, Personal, Stocks/Shares: Sermonix. D.G. Stover: Financial Interests, Personal, Advisory Board: Novartis. N. Bagegni: Financial Interests, Institutional, Research Grant: Ambrx Inc, AstraZeneca Pharmaceuticals LP, Biovica International AB, Daiichi Sankyo, Novartis, Pfizer, Sarah Cannon Development Innovations LLC, Seattle Genetics, Sermonix, Xcovery Hholdings Company LLC. G.A. Vidal: Financial Interests, Personal and Institutional, Advisory Role: Roche/Genetech, Novartis, Eli-Lilly, Gilead, Puma, Pfizer, AstraZeneca, Biotheranautics, Daiichi Sankyo, Concerto Al; Financial Interests, Personal, Training: Eli-Lilly; Financial Interests, Institutional, Research Grant: Roche/Genetech, Puma, Celcuity, Merck, BMS, Eli-Lilly, AstraZeneca, Pfizer, Gilead, GSK; Financial Interests, Personal, Ownership Interest: Oncodisc. A. Brufsky: Financial Interests, Personal, Advisory Role: AstraZeneca, Pfizer, Novartis, Lilly, Genentech/Roche, SeaGen, Daiichi Sankyo, Merck, Agendia, Sanofi, Puma; Financial Interests, Institutional, Research Grant: Agendia, AstraZeneca. H.S. Rugo: Financial Interests, Institutional, Research Grant: Pfizer, Merck, Novartis, Lilly, Roche, Daiichi, Seattle Genetics, Macrogenics, Sermonix, Boehringer Ingelheim, Polyphor, AstraZeneca, Ayala, Astellas, Gilead; Financial Interests, Personal, Other, Honoraria: Puma, Samsung, NAPO. D.J. Portman: Financial Interests, Personal, Full or part-time Employment: Sermonix; Financial Interests, Personal, Stocks/Shares: Sermonix. E. Gal-Yam: Financial Interests, Personal, Other, Honoraria: Eli-Lilly, Novartis, Pfizer, Roche, AstraZeneca, MSD.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.